Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Regeneron

- PMLiVE

Sanofi set to acquire Kiadis for €308m

Acquisition will see French pharma gain access to NK-cell platform

- PMLiVE

Regeneron halts enrolment of severely ill patients in COVID-19 antibody trial

Trial modified based on recommendations from independent data monitoring committee

Sanofi reception

Sanofi and Translate Bio eye launch of phase 1/2 COVID-19 vaccine study

Preclinical data for mRNA-based vaccine supports clinical development

- PMLiVE

Regeneron scores first FDA approval for Ebola antibody treatment

Treatment cut mortality rate in study based in the Democratic Republic of Congo

- PMLiVE

Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail

If approved, the US government will make initial doses available at no cost

- PMLiVE

Regeneron’s COVID-19 antibody cocktail reduces viral load and alleviates symptoms

Investigational treatment also helped patients recover faster

- PMLiVE

Sanofi, GSK to launch human trials of COVID-19 vaccine

Vaccine combines Sanofi’s baculovirus expression system and GSK’s AS03 adjuvant

- PMLiVE

Regeneron launches phase 3 COVID-19 antibody trial in the UK

Drug cocktail will be evaluated in patients hospitalised with COVID-19

Sanofi reception

Translate Bio, Sanofi’s COVID-19 vaccine proves promising in animal studies

Vaccine was able to induce neutralising antibodies and T-cell responses

- PMLiVE

Roche, Regeneron partner on COVID-19 antibody cocktail

Collaboration agreement will bolster global development and manufacturing capabilities

Sanofi reception

Sanofi bolsters pipeline with $3.7bn deal for Principia Biopharma

French drugmaker will gain access to a portfolio of BTK inhibitors

Sanofi reception

Sanofi faces manslaughter allegations in France over Depakine deaths

Charges relate to deaths of four babies whose mothers took anti-epileptic drug during pregnancy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links